Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6 studies found for:    vorinostat, prostate
Show Display Options
Rank Status Study
1 Active, not recruiting Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Drug: bicalutamide;   Drug: leuprolide acetate;   Drug: goserelin acetate;   Drug: vorinostat;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
2 Recruiting Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
Conditions: Prostate Cancer;   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: vorinostat;   Drug: temsirolimus;   Other: laboratory biomarker analysis;   Procedure: positron emission tomography/computed tomography
3 Completed
Has Results
Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer
Conditions: Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: vorinostat;   Other: laboratory biomarker analysis
4 Completed Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Prostate Cancer;   Small Intestine Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: vorinostat
5 Terminated Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
Condition: Non-small Cell Lung, Prostate, Bladder/Urothelial Cancers.
Interventions: Drug: vorinostat (suberoylanilide hydroxamic acid);   Drug: docetaxel
6 Completed Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
Condition: Cancer
Intervention: Drug: vorinostat

Indicates status has not been verified in more than two years